• Planned and implemented productive synthetic routes to molecules of interest for hit confirmation and hit to lead SAR generation across a number of therapeutic areas within the company's portfolio.• Contributed to writing up SOP’s for post-selection chemistry protocols.

• Worked on a drug discovery program aimed at pursuing small molecule inhibitors for a CNS disorder.• Contributed to designing efficient synthetic routes and helped solve synthetic challenges encountered by external CRO’s - active participation in weekly teleconferences.• Successfully completed a multi-step synthesis of a challenging macrocycle, enabling the team to make a key go/no-go decision on viability of the series. • Applied structure-based drug design, by working very closely with computational chemists, to design new target molecules for lead generation and lead optimization. • Served as the company representative on the organizing committee for the 2019 BSOBC symposium.

• As part of a team, served as a significant contributor to the discovery of a development candidate and a submitted patent application. • Designed and executed multi-step synthesis of challenging medicinal chemistry targets, delivering approximately 350 compounds in two years.• Evaluated complex data sets to inform future design and synthesis. • Optimized lead compounds for potency, selectivity, physiochemical properties, in vitro ADME and PK by coupling multivariant SAR analysis with hypothesis driven medicinal chemistry principles. • Productively interacted with cross-functional scientists by communicating, sharing insights and outlining progress of goals in a multi-disciplinary setting.• Performed scale-up of important lead molecules for use in DMPK and efficacy studies in animals.

• Employed modern hit-to-lead medicinal chemistry techniques, including the use of structure-based drug design in a Tuberculosis project.• As lead chemist, synthesized numerous synthetically challenging diaminopyrimidine compounds that were submitted for biological testing.• Facilitated discussion and exchanged ideas and medicinal chemistry hypotheses with our external collaborators through chemTraX (visual workflow management application).

• Applied medicinal chemistry knowledge and synthetic expertise to drug discovery projects emerging from Colorado’s research institutions.• Enhanced research programs by synthesizing novel, proprietary compounds that had the potential to be patented and used for obtaining additional federal funding for principal investigators. • Successfully designed and synthesized a novel series of imidazopyradazines that had potential implications as Flavivirus inhibitors.• Applied the results of structure based drug design to guide and make strategic decisions on medicinal chemistry SAR efforts.

• Carried out medicinal chemistry hit-to-lead efforts by designing and synthesizing potential drug candidate molecules for biological testing in drug discovery projects.• Optimized a series of quinazolinediones that showed very promising cellular activity and in vitro ADME data against the human Respiratory Syncytial Virus (RSV). This work led to the filing of a patent application. • Prepared and presented project updates to external collaborators and consultants. • Assisted with the preparation and writing up of journal manuscripts and NIH probe reports.• Served as key member of a small team that assisted with the writing up of “Principles of Asymmetric Synthesis.” 2nd Edition, Robert E. Gawley and Jeffrey Aubé, Elsevier: Oxford, 2012, 555 pp.

• Worked on synthetic efforts towards the total synthesis of Lomaiviticin B - a potent antitumor antibiotic that has been found to exhibit DNA-damaging activity.• Designed and executed multi-step synthesis toward the central core: successfully carried out the key enantioselective Diels-Alder reaction step in synthetic route resulting in an advanced intermediate containing six contiguous stereocenters.

• Worked on synthetic efforts towards the total Synthesis of Exiguamine A - a potent inhibitor against tumor cells.• Performed multi-step synthesis (carried out reactions up to a 100 gram scale). • Effectively synthesized three fragments required for construction of Exiguamine A. • Successfully carried out the key Mukaiyama Michael addition step in proposed synthetic route on a model system.